ストックスクリーナーアプリを入手
25.56
0.02%
0.010
前日終値:
$25.55
開ける：
$25.52
24時間の取引高:
6.90M
Relative Volume:
0.17
時価総額：
$148.25B
収益：
$63.63B
当期純損益:
$8.03B
株価収益率:
18.13
EPS:
1.41
ネットキャッシュフロー:
$9.84B
1週間 パフォーマンス:
-2.50%
1か月 パフォーマンス:
-3.27%
6か月 パフォーマンス:
-11.79%
1年 パフォーマンス:
-7.38%
1日の値動き範囲:
$25.42
$25.63
1週間の範囲:
$25.42
$26.52
52週間の値動き範囲:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.55 | 148.25B | 63.63B | 8.03B | 9.84B | 1.41 |
|
LLY
Lilly Eli Co
|
842.65 | 750.38B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
201.53 | 353.16B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
161.81 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
72.45 | 334.39B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
88.07 | 235.20B | 64.17B | 17.12B | 18.10B | 6.73 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program - Quantisnow
Drug Co. Wants Fed. Circ. To Undo Pfizer COVID Patent Win - Law360
Pfizer: Undervalued Defensive Play - Yahoo Finance
Pfizer Is Trading As If It's 2009 Again (NYSE:PFE) - Seeking Alpha
Which is the Healthiest Investment: Merck or PfizerF.A.S.T. GraphsCommentaries - Advisor Perspectives
Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day - TradingView
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars? - Crowell & Moring LLP
Is Pfizer (PFE) The Best Affordable Stock To Buy According To Hedge Funds? - Insider Monkey
Pfizer Is A Dirt-Cheap High-Yield Stock, But Is It A Buy? - Barchart
China touted its business potential at a meeting with Apple, Pfizer and other US companies - Українські Національні Новини
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy? - Zacks Investment Research
Pfizer Inc. (PFE) Stock: Is This Healthcare Giant the Bargain of 2025? - MoneyCheck
Epinephrine Market Is Booming Worldwide 2025-2032 | Pfizer, - openPR
China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment' - MSN
China reassures Apple, Pfizer, Cargill, others of business potential - TradingView
China's vice premier reassures Apple, Pfizer, Cargill, others of business potential - TradingView
Is Pfizer Inc. (PFE) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
Former Pfizer chief scientist joins Immunai’s board of directors - The Jerusalem Post
With 67% ownership, Pfizer Inc. (NYSE:PFE) boasts of strong institutional backing - Yahoo Finance
Pfizer: Bulls Need To Check Out Its Graham P/E - Seeking Alpha
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - The Motley Fool
Looking For Yields: Pfizer, Spire, And TriCo Bancshares Are Consistent Moneymakers - Benzinga
Pfizer Wraps Up Haleon Exit With $3.3 Billion Stake Sale - MSN
Chemistry Students Explore Cutting-Edge Technology at Pfizer Laboratories - CSUF News
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - Yahoo Finance
Pfizer Completes Sale of Entire Stake in Haleon PLC - TipRanks
Alnylam (ALNY) Heart Drug Amvuttra Wins Expanded Approval, Challenging Pfizer - Bloomberg
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - Yahoo Finance
Haleon Completes GBP170 Million Share Buyback Deal With Pfizer -March 21, 2025 at 09:16 am EDT - Marketscreener.com
Alnylam shares rise on expanded heart drug approval -March 21, 2025 at 07:32 am EDT - Marketscreener.com
Haleon PLC Completes Share Repurchase from Pfizer - TipRanks
Rx Rundown: AstraZeneca, Pfizer, Novartis and more - MM+M Online
Pfizer to Exit Sensodyne-Maker Haleon With Final Stake Sale - MSN
Dyslexia Treatment Market Is Booming Worldwide 2025-2032 | - openPR
Chemotherapy Market Overall Study Report 2025-2032 | AstraZeneca, Pfizer Inc., Novartis AG, GSK plc., Sanofi - openPR
Pfizer’s Wall Street critic-turned-executive digs into the company’s problems, obesity plans - STAT
Lobbying Update: $2,390,000 of PFIZER INC. lobbying was just disclosed - Nasdaq
US FDA approves Alnylam's drug for rare heart condition -March 20, 2025 at 05:56 pm EDT - Marketscreener.com
Is Pfizer Stock A Sell With A Looming First-Quarter Slowdown? - Investor's Business Daily
3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025 - Nasdaq
Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B - Yahoo Finance
Pfizer sells 7.3% stake in Haleon for $3.3bn - Yahoo Finance
Pfizer Independent Medical Education Grant Program (Switzerland) - fundsforNGOs
Pfizer (PFE) Stock Dips While Market Gains: Key Facts - Yahoo Finance Australia
Haleon Agrees to Buy Back Over 44 Million Shares From Pfizer -March 19, 2025 at 11:03 am EDT - Marketscreener.com
Pfizer Inc. (PFE): The Most Undervalued Biotech Stock to Invest In - Insider Monkey
Pfizer sells entire Haleon stake for $3.24 billion - Reuters
Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion - Benzinga
Pfizer Sells Final Haleon Shares for $3.2B, Ends Stake in Consumer Healthcare Giant - TradingView
Narcotics Analgesics Market Detailed In New Research Report 2025 | Pfizer Inc., Teva Pharmaceuticals, Allergan plc - openPR
Pfizer stock in focus after Haleon stake sale (PFE:NYSE) - Seeking Alpha
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
2.11%
1.08%
大文字化:
|
ボリューム (24 時間):